Drugs and Devices

New warning added for gonadotropin-releasing hormone agonists

The U.S. Food and Drug Administration has asked manufacturers to add new labeling warnings for gonadotropin-releasing hormone (GnRH) agonists, mostly used to treat men with prostate cancer. The warnings would note the potential risk of heart disease and diabetes in men treated with these medications. Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230334.htm.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares